KRAS G13D and BRAF V600E, two MAPK family members, increase resistance to erlotinib, gefitinib, and crizotinib in NSCLC and contribute to resistance against FGFR inhibitors (201). This evidence concerns the gene KRAS and non-small cell lung carcinoma.